Quarterly ResultAug 6, 2026, 04:23 PM
Lineage Cell Q2 Net Income $1.5M; Cash Runway into Q3 2028
AI Summary
Lineage Cell Therapeutics reported a net income of $1.5 million for Q2 2026, a significant improvement from a $30.5 million net loss in Q2 2025, with basic EPS of $0.01. The company's cash, cash equivalents, and marketable securities of $50.8 million are expected to fund operations into Q3 2028. Key business updates include positive 3-year clinical data for OpRegen, progress with the COR1 corneal endothelial disease program, and advancements in other pipeline assets like OPC1, ILT1, and ReSonance.
Key Highlights
- Q2 2026 net income attributable to Lineage was $1.5 million, up from a $30.5 million net loss in Q2 2025.
- Basic earnings per share for Q2 2026 was $0.01, compared to a loss of $0.13 in Q2 2025.
- Total revenues for Q2 2026 decreased to $1.1 million from $2.8 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $50.8 million as of June 30, 2026.
- Cash runway is projected to support planned operations into Q3 2028.
- Positive 3-year Phase 1/2a clinical data for OpRegen (RG6501) was featured.
- Preclinical COR1 program for corneal endothelial disease is advancing, with in-vivo data expected in 2026.
- R&D expenses increased to $4.8 million in Q2 2026 from $3.1 million in Q2 2025.
Price Impact
More from LCTX